Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...
Gilead licenses Leo Pharma's oral STAT6 portfolio for inflammatory diseases in $250M upfront deal, potentially worth $1.7B, ...
Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule ...
Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...
A statement from Gilead indicates that the deal is likely to lower its 2025 GAAP and non-GAAP earnings per share by $0.15 to ...
Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...
GlobalData on MSN4d
Gilead and LEO Pharma link on programmes for inflammatory conditionsGilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...
Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25Kymera plans to initiate a KT-621 Phase 1b trial in atopic ...
These next-generation STAT6 inhibitors demonstrate excellent oral bioavailability, cell permeability, and metabolic stability, and do not target STAT6 for degradation. DeepCure expects to select a ...
Gilead Sciences and Danish dermatology specialist LEO Pharma announced a strategic partnership, marking another move outside ...
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...
Gilead Sciences Inc. and LEO Pharma have partnered to accelerate the development and commercialization of LEO Pharma’s small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback